Use of In Vivo Animal Models to Assess Drug-Drug Interactions

被引:2
|
作者
Prueksaritanont, Thomayant [1 ]
机构
[1] Merck Res Labs, Dept Drug Metab & Pharmacokinet, West Point, PA 19486 USA
关键词
CHIMPANZEE PAN-TROGLODYTES; SPECIES-DIFFERENCES; RHESUS-MONKEY; OXIDATIVE-METABOLISM; RENAL ELIMINATION; CYNOMOLGUS MONKEY; ENZYME-ACTIVITIES; P-GLYCOPROTEIN; ORGANIC ANION; PHASE-I;
D O I
10.1007/978-1-4419-0840-7_11
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this chapter, theoretical basis and specific examples are presented to illustrate the utility of the animal models in assessing and understanding the underlying mechanisms of DDIs. In vivo assessments in an appropriate animal model are considered key to help verify in vivo relevance of in vitro studies and substantiate a basis for extrapolating in vitro human data to clinical outcomes. From a pharmacokinetic standpoint, an important consideration for successful selection of the animal model is based on broad similarities to humans in key physiological and biochemical parameters governing drug absorption, distribution, metabolism, or excretion (ADME) process of interest for both the interacted and the interacting drugs. Also equally important are specific in vitro and/or in vivo experiments demonstrating animal human similarities, usually both qualitative and quantitative, in the ADME property/process under investigation. Additional insights can also be gained with the use of knockout animals lacking specific drug transporters or drug-metabolizing enzymes and/or transgenic animal models with humanized mouse lines expressing specific drug transporters and/or metabolizing enzymes of interest.
引用
收藏
页码:283 / 297
页数:15
相关论文
共 50 条
  • [21] Absorption Models to Examine Bioavailability and Drug-Drug Interactions in Humans
    Rizwan, Ahsan Naqi
    Brouwer, Kim L. R.
    ENZYME- AND TRANSPORTER-BASED DRUG-DRUG INTERACTIONS: PROGRESS AND FUTURE CHALLENGES, 2010, : 343 - 370
  • [22] Conceptual models of drug-drug interactions: A summary of recent efforts
    Herrero-Zazo, Maria
    Segura-Bedmar, Isabel
    Martinez, Paloma
    KNOWLEDGE-BASED SYSTEMS, 2016, 114 : 99 - 107
  • [23] Pharmacointeraction Network Models Predict Unknown Drug-Drug Interactions
    Cami, Aurel
    Manzi, Shannon
    Arnold, Alana
    Reis, Ben Y.
    PLOS ONE, 2013, 8 (04):
  • [24] Drug-drug interactions in man:: predictive value of in vitro models
    Weber, F
    Becquemont, L
    THERAPIE, 2000, 55 (04): : 569 - 575
  • [25] Dealing with the complex drug-drug interactions: Towards mechanistic models
    Varma, Manthena V.
    Pang, K. Sandy
    Isoherranen, Nina
    Zhao, Ping
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2015, 36 (02) : 71 - 92
  • [26] Cellular models for ADMET predictions and evaluation of drug-drug interactions
    Riley, RJ
    Kenna, JG
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (01) : 86 - 99
  • [27] Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review
    Volpe, Donna A.
    Xu, Yun
    Sahajwalla, Chandrahas G.
    Younis, Islam R.
    Patel, Vikram
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (12) : 2983 - 2991
  • [28] Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug-Drug Interactions of Phenytoin
    Rodriguez-Vera, Leyanis
    Yin, Xuefen
    Almoslem, Mohammed
    Romahn, Karolin
    Cicali, Brian
    Lukacova, Viera
    Cristofoletti, Rodrigo
    Schmidt, Stephan
    PHARMACEUTICS, 2023, 15 (10)
  • [29] Drug use survey to identify significant drug-drug interactions and assess clinical importance in the outpatient setting of a tertiary care hospital
    Chowdhury, Koustuv
    Hazra, Avijit
    Ghosh, Soumitra
    Choudhury, Shouvik
    INDIAN JOURNAL OF PHARMACOLOGY, 2024, 56 (03) : 172 - 177
  • [30] COCAINE DRUG-DRUG INTERACTIONS
    ROSEN, EH
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1992, 12 (06) : 445 - 445